These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24361860)

  • 1. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
    Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
    Tsuchiya K; Ohuchi M; Yamane N; Aikawa H; Gatanaga H; Oka S; Hamada A
    Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28762239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
    Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
    Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
    J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
    Yamada E; Takagi R; Moro H; Sudo K; Kato S
    PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
    Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.
    Srivastava P; Moorthy GS; Gross R; Barrett JS
    PLoS One; 2013; 8(6):e63305. PubMed ID: 23755102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
    Long MC; Bennetto-Hood C; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 May; 867(2):165-71. PubMed ID: 18430616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection.
    Wang X; Penchala SD; Amara A; Else L; McClure M; Boffito M
    Ther Drug Monit; 2016 Jun; 38(3):327-31. PubMed ID: 26859200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
    West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.
    Merschman SA; Vallano PT; Wenning LA; Matuszewski BK; Woolf EJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 857(1):15-24. PubMed ID: 17644453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma.
    Schauer AP; Sykes C; Cottrell ML; Imaz A; Podzamczer D; Kashuba AD
    J Pharm Biomed Anal; 2022 Oct; 220():115010. PubMed ID: 36030752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.
    Ter Heine R; Hillebrand MJ; Rosing H; van Gorp EC; Mulder JW; Beijnen JH; Huitema AD
    J Pharm Biomed Anal; 2009 Feb; 49(2):451-8. PubMed ID: 19128911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
    PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
    de Dios K; Manibusan A; Marsden R; Pinkstaff J
    J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.
    Grégoire M; Deslandes G; Renaud C; Bouquié R; Allavena C; Raffi F; Jolliet P; Dailly E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():1-9. PubMed ID: 25261833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
    Djerada Z; Feliu C; Tournois C; Vautier D; Binet L; Robinet A; Marty H; Gozalo C; Lamiable D; Millart H
    J Pharm Biomed Anal; 2013 Dec; 86():100-11. PubMed ID: 23995753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.